Form PRE 14A DBV Technologies S.A. For: 1 May
- Investing.com
- English (USA)
- English (UK)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
DBV Technologies (DBVT)
The DBV Technologies share price today is 19.730, view NASDAQ DBVT stock exchange data. Track the latest DBV Technologies share price with real-time updates on DBVT stock performance including market cap, day range, 52-week range and dividend yield. Access DBVT charts, earnings dates and analyst estimates to support your investment decisions.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
19.645
19.910
52 wk Range
7.526
26.185
DBVT is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
19.64519.910
52 wk Range
7.52626.185
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
DBVT Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Price Target
41.121
Upside
+108.42%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Analysts do not anticipate the company will be profitable this year
- DBV Technologies receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- Form PRE 14A DBV Technologies S.A. For: 1 May
- Investing.com
- DBV Technologies receives Investment Bank Analyst Rating Update
- Investing.com
Pro - DBV Technologies receives Investment Bank Analyst Rating Update
- Investing.com
Pro
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell
Analyst Ratings
5 Buy
0 Hold
1 Sell
Ratings:
6 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 41.121
(+108.42% Upside)
DBV Technologies SWOT Analysis
Allergy Innovation | Explore DBV Technologies' groundbreaking Viaskin Peanut patch, offering a non-invasive solution for peanut allergies in children with promising clinical results |
Market Potential | Delve into the projected $2 billion annual peak sales for Viaskin Peanut, driven by strong physician intent and a growing patient base |
Financial Outlook | Learn about DBV's improved financial position, with $128 million in cash and potential for $180 million more, despite current cash burn concerns |
Analyst Perspectives | Discover varied analyst price targets ranging from $10 to $21, reflecting optimism about DBV's future prospects in the allergy treatment market |
DBV Technologies Earnings Call Summary for Q2/2024
- DBV Technologies advances Viaskin Peanut trials; VITESSE Phase 3 enrollment for ages 4-7 to complete by Q3 end
- Net loss of $60.5M in H1 2024; cash runway extended to Q1 2025 through cost-saving measures
- FDA feedback pending on labeling approach for toddlers aged 1-3; EPITOPE trial year 3 results expected later in 2024
- Operating expenses at $65M, including $24M non-recurring costs; cash used in operations totaled $70M
- Company optimistic about FDA agreement on labeling; emphasizes patient experience data importance
Last Updated: 01-08-2024, 04:24 am
Read Full TranscriptEarnings
Latest Release
26-03-2026
EPS / Forecast
-0.24 / --
Revenue / Forecast
645K / --
Compare DBVT to Peers and Sector
Metrics to compare | DBVT | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipDBVTPeersSector | |
|---|---|---|---|---|
P/E Ratio | −7.1x | 4.2x | −0.5x | |
PEG Ratio | −0.21 | 0.17 | 0.00 | |
Price/Book | 5.7x | 3.1x | 2.6x | |
Price / LTM Sales | 206.6x | 3.8x | 3.2x | |
Upside (Analyst Target) | 134.0% | 70.9% | 47.8% | |
Fair Value Upside | Unlock | 10.3% | 5.9% | Unlock |
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis. The company’s earlier stage research programs include celiac disease. In addition, the company develops Viaskin technology platform, a platform to potentially treat food allergy. It has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Châtillon, France.
Ownership
Ownership Overview
Top Holders
FAQ
What Is the DBV Technologies (DBVT) Share Price Today?
The DBV Technologies share price today is 19.730.
What is the current DBV Technologies (DBVT) share price and day range?
As of 09-05-2026, the DBV Technologies share price is 19.730, with a previous close of 19.990. The share price has ranged from 19.645 to 19.910 today, while the 52-week range spans from 7.526 to 26.185.
What Is the DBV Technologies Market Cap?
As of today, DBV Technologies market cap is 1.190B.
What Is the DBV Technologies (DBVT) Share Price Target?
The average 12-month share price target for DBV Technologies is 41.121, with a high estimate of 55.25279906 and a low estimate of 6.01060695. 5 analysts recommend buying, while 1 suggest selling, with an overall rating of Buy and +108.42% Upside potential.
What Is DBV Technologies's Earnings Per Share (TTM)?
The DBV Technologies EPS (TTM) is -0.758.
From a Technical Analysis Perspective, Is DBVT a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
What Stock Exchange Does DBV Technologies Trade On?
DBV Technologies is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for DBV Technologies?
The stock symbol for DBV Technologies is "DBVT."
How Many Times Has DBV Technologies Stock Split?
DBV Technologies has split 2 times.
How Many Employees Does DBV Technologies Have?
DBV Technologies has 126 employees.
What Is the DBVT Premarket Price?
DBVT's last pre-market stock price is 19.680. The pre-market share volume is 2,100.000, and the stock has changed by -0.310, or -1.550%.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.